Recursion Pharmaceuticals, Inc.
RXRX
$3.16
-$0.15-4.53%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 23.79% | 41.97% | 39.56% | -69.29% | -76.23% |
| Total Depreciation and Amortization | -23.82% | 1.77% | 50.40% | 192.35% | 165.93% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -30.23% | -56.99% | -40.10% | 68.94% | 166.51% |
| Change in Net Operating Assets | -152.80% | -33.37% | 494.35% | -9,860.61% | 579.32% |
| Cash from Operations | -38.64% | 38.54% | 60.09% | -98.16% | 7.06% |
| Capital Expenditure | 98.60% | 85.92% | 4.16% | 94.67% | -166.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 27.95% | 92.00% | 100.00% | -- | 11.40% |
| Cash from Investing | 66.27% | 95.35% | -100.45% | 44.13% | -38.88% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -8.01% | -7.87% | -3.14% | 7.00% | -7,915.38% |
| Issuance of Common Stock | -- | -- | 953.16% | 1,251.90% | -62.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 482.88% | -181.42% | -- | -- | -- |
| Cash from Financing | -101.30% | -108.56% | 1,140.77% | 1,426.79% | -62.88% |
| Foreign Exchange rate Adjustments | -91.22% | -179.29% | 160.11% | 363.77% | 7,943.22% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -538.92% | 5.46% | -48.10% | 384.09% | -86.02% |